Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65 safe harbor levels

This article was originally published in The Rose Sheet

Executive Summary

Di(2-ethylhexyl)phthalate (DEHP) poses no significant risk at levels of 310 µg/day, according to September status report on Prop 65 safe harbor levels. Released by California's Office of Environmental Health Hazard Assessment, report also designates No Significant Risk Level for perfume ingredient Catechol as a "second priority" for the agency. Prop 65 requires safe harbor warnings on products containing ingredients known to cause cancer or reproductive toxicity. OEHHA announced its intent to add DEHP and Catechol to Prop 65 list in April and May, respectively (1"The Rose Sheet" April 28, 2003, In Brief and 2"The Rose Sheet" May 26, 2003, In Brief)...

You may also be interested in...



DEHP Prop 65 listing

California Office of Environmental Health Hazard Assessment announces intent to list di (2-ethylhexyl) phthalate as known to the state to cause reproductive toxicity in 1notice made available April 15. Listing is based on conclusions by the National Institute for Occupational Safety and Health and FDA demonstrating DEHP causes developmental and reproductive toxicity in laboratory animals, according to OEHHA. Objections to the listing of DEHP under Prop 65 will be accepted until May 12, agency adds. OEHHA solicited data on DEHP in 1998. A public forum was held to discuss the chemical in 1999...

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector

With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel